F-star Therapeutics Ltd is set to gain a listing on Nasdaq through a merger with Spring Bank Pharmaceuticals Inc of the US giving it a fresh source of capital to advance its pipeline of bispecific antibodies. The transaction is expected to complete in late 2020 and give F-star’s shareholders 61.2% of the new group to be called F-star Therapeutics Inc.
Eliot Forster, the current chief executive of F-star, will become president and chief executive of the combined group which will be co-located in Cambridge, UK and Cambridge, Massachusetts, US.